Explore the words cloud of the ActiTOX project. It provides you a very rough idea of what is the project "ActiTOX" about.
The following table provides information about the project.
Coordinator |
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
Organization address contact info |
Coordinator Country | Germany [DE] |
Total cost | 1˙191˙400 € |
EC max contribution | 1˙191˙400 € (100%) |
Programme |
1. H2020-EU.1.3.3. (Stimulating innovation by means of cross-fertilisation of knowledge) |
Code Call | H2020-MSCA-RISE-2018 |
Funding Scheme | MSCA-RISE |
Starting year | 2019 |
Duration (year-month-day) | from 2019-08-01 to 2023-07-31 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. | DE (MUNCHEN) | coordinator | 161˙000.00 |
2 | INOCURE SRO | CZ (PRAHA) | participant | 239˙200.00 |
3 | SZECHENYI ISTVAN UNIVERSITY | HU (GYOR) | participant | 193˙200.00 |
4 | BIOFABICS LDA | PT (PORTO) | participant | 133˙400.00 |
5 | TECHNISCHE UNIVERSITAET WIEN | AT (WIEN) | participant | 124˙200.00 |
6 | OSPIN GMBH | DE (BERLIN) | participant | 105˙800.00 |
7 | USTAV EXPERIMENTALNI MEDICINY AKADEMIE VED CESKE REPUBLIKY VEREJNA VYZKUMNA INSTITUCE | CZ (PRAHA 4) | participant | 105˙800.00 |
8 | UNIVERSITAET GRAZ | AT (GRAZ) | participant | 69˙000.00 |
9 | ORTHOSERA GMBH | AT (KREMS AN DER DONAU) | participant | 50˙600.00 |
10 | BIONEER A/S | DK (HOERSHOLM) | participant | 9˙200.00 |
Nanoparticles and new drugs are undergoing complex toxicity evaluation prior to their use in products for customers. However, the traditional pre-clinical testing protocols are delivering significant disadvantages both from ethical (animal testing) and functional (high attrition rate in clinical testing) point of view. ActiTOX reacts to this problem by the development of a novel, pre-clinical, high content, in vitro testing platform focused on the evaluation of nanoparticles/drugs via ADME (absorption, distribution, metabolism, excretion) toxicity studies. In order to advance the current state of art the project will employ biomimetic scaffolds, drug delivery systems, human induced pluripotent stem cells (iPSCs), 3D-microfluidics and modular bioreactor technology. ActiTOX aims to increase the relevance of in vitro studies and provide a scalable approach for their use in drug development and toxicological screening. In order to achieve the project goals, a training network enabling efficient short-term secondments of ER and ESR between academia and industry will be established. The cooperation between stakeholders helps closing the gap between them and oint innovation to foster the current state of the art. ActiTOX will mediate it via networking, research, training, workshop, innovation and dissemination actions in form of short-term secondments. The project fulfils the aim of a RISE project and delivers significant social impact, increases knowledge based economy and creates long lasting cooperation strengthening the European research area.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ACTITOX" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "ACTITOX" are provided by the European Opendata Portal: CORDIS opendata.
RELIABLE TECHNOLOGIES AND MODELS FOR VERIFIED WIRELESS BODY-CENTRIC TRANSMISSION AND LOCALIZATION
Read MoreIdentifying Marginal Lands in Europe and strengthening their contribution potentialities in a CO2sequestration strategy
Read MoreOutcomes of Patients’ Evidence With Novel, Do-It-Yourself Artificial Pancreas Technology
Read More